26 jul: Torsdagens aktier: Forsvarstale gav festfyrværkeri
27 jul: USA/aktier: Wall Street dansede efter Draghis pibe
26-07-2012 22:51:00

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

Relateret indhold

By Tess Stynes

Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments.

Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year.

For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion.

Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37.

Revenue increased 13% to $4.48 billion, including 8% growth in product sales.

Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion.

Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%.

However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 16:51 ET (20:51 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Nordfyns Bank Q1: Udlåns- og kundevækst sikrer godkendt start

28-04-2016 16:38:09
Trods en en mindre tilbagegang på både top- og bundlinjen har Nordfyns Bank fået en "tilfredsstillende" start på 2016. Det er særligt øget kundevækst og vækst i..

Novo: Semaglutid reducerer risikoen for hjerte-kar-tilfælde-NY2

28-04-2016 12:45:02
Novo Nordisk kan torsdag præsentere overbevisende studiedata med den nye langtidsvirkende GLP-1-analog Semaglutid, der har vist sig at reducere risikoen for hje..

Vestas vinder ordre på 76 MW til Sverige

28-04-2016 10:51:42
Den danske vindmøllevirksomhed Vestas har vundet en svensk ordre på 22 vindmøller af en samlet kapacitet på 76 MW.Ordren er afgivet af Fortum Generation AB, og ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Semaglutid reducerer risikoen for hjerte-kar-tilfælde-NY2
2
Aktier/tendens: Jyske Bank stjæler fokus i sivende marked
3
Aktier/åbning: Jyske Bank bliver sendt ned efter regnskab
4
Vestas vinder ordre på 76 MW til Sverige
5
Mærsk/SHB: Kursmål sænkes til 9500 og anbefaling til "reducer"

Relaterede aktiekurser

Amgen Inc 160,56 -0,3% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. april 2016 01:52:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20160421.1 - EUROWEB3 - 2016-04-29 01:52:39 - 2016-04-29 01:52:39 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x